Detailed Information

Cited 1 time in webofscience Cited 2 time in scopus
Metadata Downloads

Inhibition of CDK4/6 regulates AD pathology, neuroinflammation and cognitive function through DYRK1A/STAT3 signalingopen access

Authors
Lee, Hyun-juHoe, Hyang-Sook
Issue Date
Apr-2023
Publisher
Academic Press
Keywords
Abemaciclib mesylate; Cognitive function; A beta; Tau; LPS; Neuroinflammation
Citation
Pharmacological Research, v.190
Journal Title
Pharmacological Research
Volume
190
URI
http://scholarworks.bwise.kr/kbri/handle/2023.sw.kbri/137
DOI
10.1016/j.phrs.2023.106725
ISSN
1043-6618
Abstract
Repurposing approved drugs is an emerging therapeutic development strategy for Alzheimer's disease (AD). The CDK4/6 inhibitor abemaciclib mesylate is an FDA-approved drug for breast cancer treatment. However, whether abemaciclib mesylate affects A beta/tau pathology, neuroinflammation, and A beta/LPS-mediated cognitive impairment is unknown. In this study, we investigated the effects of abemaciclib mesylate on cognitive function and A beta/tau pathology and found that abemaciclib mesylate improved spatial and recognition memory by regulating the dendritic spine number and neuroinflammatory responses in 5xFAD mice, an A beta-overexpressing model of AD. Abemaciclib mesylate also inhibited A beta accumulation by enhancing the activity and protein levels of the A beta-degrading enzyme neprilysin and the alpha-secretase ADAM17 and decreasing the protein level of the gamma-secretase PS -1 in young and aged 5xFAD mice. Importantly, abemaciclib mesylate suppressed tau phosphorylation in 5xFAD mice and tau-overexpressing PS19 mice by reducing DYRK1A and/or p-GSK3 beta levels. In wild-type (WT) mice injected with lipopolysaccharide (LPS), abemaciclib mesylate rescued spatial and recognition memory and restored dendritic spine number. In addition, abemaciclib mesylate downregulated LPS-induced microglial/astrocytic activation and proinflammatory cytokine levels in WT mice. In BV2 microglial cells and primary astrocytes, abemaciclib mesylate suppressed LPS-mediated proinflammatory cytokine levels by downregulating AKT/STAT3 signaling. Taken together, our results support repurposing the anticancer drug, CDK4/6 inhibitor abemaciclib mesylate as a multitarget therapeutic for AD pathologies.
Files in This Item
There are no files associated with this item.
Appears in
Collections
연구본부 > 퇴행성 뇌질환 연구그룹 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Hyun ju photo

Lee, Hyun ju
연구본부 (퇴행성뇌질환 연구그룹)
Read more

Altmetrics

Total Views & Downloads

BROWSE